Skip to main content
PepStack
Wiki · Profile

Adipotide

FTPP · Prohibitin-targeting peptide

Metabolic & WeightPreclinical
From$7.30/mgCompare prices
MW
2557.2g/mol
Formula
C111H206N36O28S2

Adipotide is a proapoptotic peptide derived from the KLA sequence, designed to target adipose tissue through the prohibitin receptor. Researchers primarily study it for its potential role in addressing obesity and related metabolic disorders by inducing apoptosis in dysfunctional adipocytes. Key findings from recent studies indicate that Adipotide can significantly reduce body weight and serum leptin levels in diet-induced obesity models, while also promoting the reduction of ectopic fat deposits in the liver and muscle. Current research suggests that the peptide's efficacy may be enhanced when used in conjunction with nanoparticle delivery systems that specifically target adipose tissue, highlighting its promise as a novel therapeutic strategy in obesity management.

Chemical Profile

Chemical Profile

Chemical structure
Chemical Structure
FormulaC111H206N36O28S2
Molecular Weight2557.2 g/mol
CAS Number859216-15-2
PubChem CID163360068

Half-Life

INIntranasal

Not applicable

POOral

Poor bioavailability

Pharmacokinetic data is primarily derived from animal studies.

Mechanism

Mechanism of Action

Adipotide, a prohibitin-targeting peptide, induces apoptosis in adipose tissue by binding to prohibitin receptors on adipocytes and endothelial cells, activating pro-apoptotic signaling pathways. This leads to reduced adipocyte viability, decreased serum leptin levels, and enhanced lipolysis through increased adiponectin, thereby promoting weight loss and ameliorating obesity-related metabolic dysfunctions. The precise molecular mechanisms and downstream signaling pathways involved remain to be fully elucidated.

Research

12 Research Publications

354

Total Citations

5

Human/RCT

2.4

Avg. Influence

2024

Latest

Sort
Filter
#01

A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys.

Barnhart Kirstin F, et al. · Science translational medicine · 2011

HumanInfluence1.0
92
Researchers studied a new compound called adipotide in obese monkeys and found that it led to significant weight loss and improved insulin sensitivity. This compound specifically targeted fat tissue, resulting in a marked reduction of white fat. The findings suggest that adipotide could be a promising candidate for future obesity treatments in humans.

Key findings

  1. 01Researchers observed that adipotide caused targeted cell death in the blood vessels of white fat tissue.
  2. 02The treatment resulted in rapid weight loss and improved insulin resistance in obese monkeys.
  3. 03Imaging techniques confirmed a significant reduction in white adipose tissue among the treated monkeys.
PubMed
#02

Reversible On-Off Switching of Excitation-Wavelength-Dependent Emission of a Phosphorescent Soft Salt Based on Platinum(II) Complexes.

Li Jiangang, et al. · Journal of the American Chemical Society · 2021

In Vitro
64
Researchers studied a new type of phosphorescent material made from platinum(II) complexes that can change its light emission based on the wavelength of light used to excite it. They found that this material allows for precise control over its luminescence, which could be useful in various advanced technologies.

Key findings

  1. 01Researchers observed that the light emitted by the material varies depending on the wavelength of light used to excite it.
  2. 02The study demonstrated a unique ability to switch the luminescence behavior on and off as needed.
  3. 03This new phosphorescent soft salt shows promise for applications in advanced photonic technologies.
PubMed
#03

A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication.

Hossen Nazir, et al. · Journal of controlled release : official journal of the Controlled Release Society · 2013

AnimalInfluence3.0
54
Researchers observed that nanoparticle-targeted therapeutics significantly reduced body weight and ectopic fat deposits in diet-induced obesity mice, outperforming bioconjugates like Adipotide.

Key findings

  1. 01The nanoparticle-targeted therapy led to a significant decrease in body weight and serum leptin levels in diet-induced obese mice.
  2. 02This treatment reduced ectopic fat deposits in the liver and muscle, indicating improved fat metabolism.
  3. 03The therapy was delivered effectively to adipose tissue, enhancing its impact on dysfunctional fat cells.
PubMed
#04

Saturation-Tolerant Prescribed Control for Nonlinear Systems With Unknown Control Directions and External Disturbances.

Ji Ruihang, et al. · IEEE transactions on cybernetics · 2024

In VitroInfluence5.0
50
Researchers investigated a new control method for complex systems that can handle unexpected disturbances and unknown factors. They found that their approach improves system performance while maintaining safety limits, even under challenging conditions.

Key findings

  1. 01The proposed method enhances tracking performance by allowing for user-defined settling times.
  2. 02An auxiliary system was developed to address the conflict between performance and input constraints.
  3. 03The new control strategy demonstrated improved robustness against external disturbances and performance limitations.
PubMed
#05

Fatty Liver/Adipose Tissue Dual-Targeting Nanoparticles with Heme Oxygenase-1 Inducer for Amelioration of Obesity, Obesity-Induced Type 2 Diabetes, and Steatohepatitis.

Animal
35
Researchers observed that dual-targeted nanoparticles effectively induced the conversion of white adipocytes to brown adipocytes and reduced inflammation in models of type 2 diabetes and nonalcoholic steatohepatitis.
PubMed
#06

A new strategy to screen molecular imaging probe uptake in cell culture without radiolabeling using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Cheng Zhen, et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2005

In VitroInfluence2.0
24
Researchers explored a new method using mass spectrometry to quickly assess how well certain molecules, called phosphonium cations, can enter cells. They found that two specific cations, TPP and FTPP, were particularly effective at accumulating in cells, suggesting their potential use in imaging techniques for studying cell function.

Key findings

  1. 01Researchers observed that the mass spectrometry technique could detect very low levels of TPP in cells, highlighting its sensitivity.
  2. 02The study found that TPP and FTPP accumulated in cells more effectively than other tested cations.
  3. 03Researchers noted that FTPP maintained the ability to enter cells based on the cell's membrane potential, similar to TPP.
PubMed
#07

Prohibitin: targeting peptide coupled to ovarian cancer, luteinization and TGF-β pathways.

Case Report
15
The study demonstrated that increased prohibitin expression in malignant ovarian tissue correlates with decreased serum levels of LH and TGF-β, suggesting their roles in ovarian cancer progression.
PubMed
#08

Fitness-to-practise policies in Australian medical schools--are they fit for purpose?

McGurgan Paul M, et al. · The Medical journal of Australia

Human
9
Researchers studied the fitness-to-practise policies (FTPPs) used by Australian medical schools to assess their effectiveness and consistency. They found that while most schools have FTPPs, the criteria for these policies vary widely, and there is no clear evidence that these policies effectively reduce student exclusions for unprofessional behavior.

Key findings

  1. 01Most Australian medical schools use FTPPs, but the criteria and processes differ significantly between institutions.
  2. 02There was no noticeable difference in the rates of student exclusions for professional misconduct between schools with FTPPs and those without.
  3. 03The primary reason for student exclusion was persistent inappropriate behavior, often identified by the third year of study.
PubMed
#09

The effects on length of stay of introducing a fast track patient pathway for myocardial infarction: a before and after evaluation.

Laut Kristina Grønborg & Foldspang Anders · Health services management research · 2012

HumanInfluence1.0
9
Researchers studied the impact of a fast-track patient pathway for individuals with non-ST Elevation Myocardial Infarction (NSTEMI) to see if it could shorten hospital stays. They found that while patients selected for the fast track experienced a reduction in their hospital stay, the overall length of stay for all patients increased due to changes in the healthcare system.

Key findings

  1. 01Patients in the fast-track program had a mean hospital stay reduced by 3.3 days.
  2. 02Overall, patients in the fast-track period spent an average of 1.7 days longer in the hospital compared to the previous period.
  3. 03The study highlights that changes in one part of the healthcare system can affect the entire patient experience.
PubMed
#10

Fluorinated High-Valent Sn(IV) Porphyrins Show Remarkable Photodynamic Activity in Cancer Cells.

Bora Bidisha, et al. · ChemMedChem · 2024

In Vitro
2
Researchers studied a new group of fluorinated Sn(IV) porphyrins, which are compounds that can be used in photodynamic therapy for cancer. They found that these compounds showed strong activity in killing cancer cells when exposed to light, making them promising candidates for future cancer treatments.

Key findings

  1. 01Researchers observed that fluorinated Sn(IV) porphyrins are effective photosensitizers in photodynamic therapy.
  2. 02The study identified four different fluorinated Sn(IV) porphyrins with varying numbers of fluorine atoms.
  3. 03These compounds demonstrated remarkable photodynamic activity against cancer cells when activated by light.
PubMed
Safety

Safety & Handling

Research Gaps

No clinical trials involving human subjects have been conducted to evaluate the efficacy and safety of Adipotide in treating obesity and related metabolic disorders. Additionally, the long-term effects and potential adverse outcomes of using prohibitin-targeted therapies, such as those involving Adipotide, remain unclear, particularly regarding their impact on overall metabolic health and organ function.

Solubility

Adipotide is soluble in water and DMSO.

Storage & Handling

Lyophilized

Stable for 2+ years at -20°C, 12 months at 4°C

Reconstituted

Use within 14 days when refrigerated at 4°C

Avoid

Avoid repeated freeze-thaw cycles, direct light

Solvent

Bacteriostatic water or sterile saline recommended

Safety information is derived from published research and may not reflect all known risks. This is not medical advice.

Legal Status

Legal Status

🇩🇪DE

Not approved as a medicinal product. Not a controlled substance. Sale as research chemical is a legal grey area.

🇺🇸US

Not approved by the FDA. Not scheduled by the DEA.

🇦🇺AU

Not listed in the TGA schedules.

🇬🇧UK

Not approved by the MHRA as a medicinal product.

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

Community Insights

Community Insights

Publications per Year

3 total
1
13
1
17
1
22
Pricing

Price Comparison

  • BESTPeptide ProsUS
    10mg
    $72.99
    Price/mg
    $7.30/mg
    View
  • Pure Tested PeptidesUS
    5mg
    $89.00
    Price/mg
    $17.80/mg
    View
  • Peptides.netUK
    2mg
    $36.83
    Price/mg
    $18.42/mg
    View
  • BPC-157 PeptideUS
    2mg
    —
    Price/mg
    —
    View
  • BPC-157 PeptideUS
    5mg
    —
    Price/mg
    —
    View

Top 5 of 11 offers from 8 vendors. Prices updated daily.

See all Adipotide prices
Mechanism

Tools

Reconstitution Calculator

Calculate reconstitution volumes for Adipotide

Serum Level Visualizer

Visualize Adipotide serum levels over time

Mechanism

Related Peptides

LiraglutideRetatrutideTirzepatide5-Amino-1MQGLP-1Semaglutide

Track Adipotide in PepStack

Log your research cycles, set reminders and visualize serum levels.

Download on theApp StoreGet it onGoogle Play
Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer